Volver al buscador
FDAFDA · Alimentos y medicamentos·N.º oficial Z-2159-2012

Cobas KRAS Mutation Test for In Vitro Diagnostic Use Product Usage: Usage: The Cobas KRAS Mutation Test, for use with the Cobas 4800 System, is a real-time PCR test intended for the identification of mutations in codons 12, 13 and 61 of the KRAS gene in DNA derived from formalin-fixed paraffin-embedded human colorectal cancer (CRC).

Publicado el 15 de agosto de 2012 · Inicio del retiro: 24 de febrero de 2012

Resumen

FDA registra el retiro Z-2159-2012 de dispositivos médicos de Clase III, publicado el 15 de agosto de 2012 e iniciado el 24 de febrero de 2012. Empresa responsable: Roche Molecular Systems, Inc.; Estado: Finalizado; Cantidad reportada: 264 kits to 13 EU countries; 2 kits to Canada and 33 kits to 11 countries in the Rest of the World; Lote: 05852170190; Lot P06778. La Clase III indica que no es probable que el producto cause consecuencias adversas para la salud.

Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.

Qué peligro representa

During the real-time stability testing for the cobas KRAS Mutation Test on the commercial lot PO6778, it was identified that the kit was just within specifications for the codon 61 peak height ratio, and that the kit has trended towards the upper specification limit at the 6 month time point but did passed the 6 month stability testing. The kit is labeled for 9 months shelf life stability. The d

Qué hacer

Voluntary: Firm initiated · E-Mail

Recibe un correo cuando FDA publique un retiro como este

Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.

Detalles del retiro

Fabricante
Roche Molecular Systems, Inc.
Distribuidor
Worldwide Distribution - including the countries of Austria, Belgium, Czech Republic, Denmark, Germany, Italy, Luxemburg, Netherlands, Poland, Slovakia, Slovenia, Spain, United Kingdom, Canada, Chile, Greenland, Hong Kong, Israel, Malaysia, New Zealand, Philippines, S. Africa, Switzerland, Taiwan and Turkey.
Lote
05852170190; Lot P06778
Clasificación de riesgo
Class III
Área (FDA)
device
País
United States

Retiros relacionados

Preguntas sobre este retiro

¿Cobas KRAS Mutation Test for In Vitro Diagnostic Use Product Usage: Usage: The Cobas KRAS Mutation Test, for use with the Cobas 4800 System, is a real-time PCR test intended for the identification of mutations in codons 12, 13 and 61 of the KRAS gene in DNA derived from formalin-fixed paraffin-embedded human colorectal cancer (CRC). fue retirado del mercado?

Sí. FDA publicó el retiro Z-2159-2012 el 15 de agosto de 2012. Peligro reportado: During the real-time stability testing for the cobas KRAS Mutation Test on the commercial lot PO6778, it was identified that the kit was just within specifications for the codon 61 peak height ratio, and that the kit has trended towards the upper specification limit at the 6 month time point but did passed the 6 month stability testing. The kit is labeled for 9 months shelf life stability. The d

¿Qué debo hacer si tengo este producto?

Voluntary: Firm initiated · E-Mail